Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Dacarbazine for Metastatic Melanoma
NCT00006200Phase 2Unknown
- Sponsor
- National Center for Research Resources
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of thalidomide in melanoma, sponsored by National Center for Research Resources. Primary endpoints: Response Rate and Safety and Toxicity. Status: unknown.
02
Drugs
thalidomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00006200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006200.